CRISPR May Resolve Uncertainty in Hereditary Cancer Genetic Tests

BRCA1 is an important DNA repair gene closely associated with breast cancer; a normally functioning BRCA gene thus prevents tumor formation. If this gene undergoes a mutation , the risk of several cancers, particularly breast and ovarian cancer, rises substantially. Genetic analyses performed in women for breast or ovarian cancer screening reveal many variants (different mutations) in the BRCA1 gene. Whether these variants are pathogenic (harmful) is unknown. This prevents effective cancer risk assessment. In September 2018, Naturepublished a study in which the CRISPR gene-editing technique was used to examine the BRCA1 gene and whether more than 4000 mutations were pathogenic (increased cancer risk). This development is highly important for patients with unknown BRCA1 variants identified by genetic analysis.

- Hereditary cancers and their genes Certain mutations in the BRCA1 gene are known to increase a person's susceptibility to breast and ovarian cancer. When genetic analysis identifies a pathogenic BRCA1 mutation in a healthy person, genetic counseling is recommended. Genetic counseling involves risk-reduction planning, such as regular screening programs or preventive surgery. However, whether some variants are pathogenic remains uncertain. Although BRCA1 is a very well-known gene, not all its mutations have been examined. This study used CRISPR to investigate whether more than 4000 mutations were pathogenic. - Related topic: Why did Angelina Jolie have both breasts removed? As is known, CRISPR is a genetic engineering technique that enables desired changes to a gene. CRISPR was used to create thousands of mutations in the BRCA1 gene and test their effects in human cells in the laboratory. Whether these mutations were pathogenic was successfully determined.
What does this study mean for us? • After 20 years of research on the BRCA1 gene, 4000 mutations whose effects had remained uncertain were successfully analyzed using CRISPR. • This study may enable effective risk planning for patients with uncertain variants in BRCA1 gene analyses. • CRISPR continues to revolutionize cancer research. Similar studies have begun on other cancer genes. * - Who should undergo genetic testing for hereditary breast cancer? - Is ovarian cancer hereditary? What are the genetic risk factors?
Sources
Accurate classification of BRCA1 variants with saturation genome editing.
Nature, 12 September 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.